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Summary 
Objective: To study the safety and tolerability of Lymfactin R © treatment combined with 
microvascular lymph node transfer surgery in patients with upper limb lymphedema. 
Background: Upper limb lymphedema is a common clinical challenge after breast cancer 
surgery and/or radiotherapy. Lymfactin R © is an adenovirus type 5–based gene therapy involv- 
ing expression of human vascular endothelial growth factor C (VEGF-C) in the damaged tissue. 
It aims to correct deficient lymphatic flow by promoting the growth and repair of lymphatic 
vessels. 
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Methods: In Phase I, Lymfactin R © was combined with microvascular lymph node transfer surgery 
to study the safety and tolerability of Lymfactin R © and the biodistribution of the viral vector in 
patients with upper limb lymphedema. 
Results: Fifteen patients with breast cancer–associated secondary lymphedema of the upper 
arm were recruited between December 2016 and February 2018. Three patients received a 
lower dose (1 × 10 10 ) and 12 a higher dose (1 × 10 11 ) of viral particles, respectively. No dose- 
limiting toxicities were observed, and the study was completed with the pre-determined max- 
imum dose. Commonly reported adverse events during the 12-month follow-up were common 
cold, fever, gastroenteritis, pain in the operation area, headache, muscle ache and elevated 
liver enzymes. Serious adverse events consisted of two erysipelas infections in the lymphedema 
arm (requiring hospitalization) and one hematoma of the flap donor site. 
Conclusions: After 12 months’ follow-up, results indicate that Lymfactin R © is well tolerated. 
The study continues with a 36-months efficacy and 5 years safety follow-up of the patients. The 
oncological safety aspects of Lymfactin R © will require a longer follow-up period. 
© 2020 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Pub- 
lished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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he treatment of breast cancer often includes axillary 
ymph node dissection followed by radiation therapy. The 
ncidence of lymphedema is more than 20% in patients who 
ave undergone axillary lymph node dissection. 1 The risk 
ignificantly increases in patients receiving radiotherapy 
 , 2 . Initial lymphedema often develops into chronic lym- 
hedema, a progressive disease characterized by the accu- 
ulation of interstitial fluid, leading to pitting edema of the
ffected limb and gradually to irreversible accumulation of 
bro-adipose tissue and non-pitting edema. During the past 
ecade, vascularized lymph node transfer surgery (VLNT) 
as been gaining popularity. This procedure seems to pro- 
ide at least some benefit to the patients. 3-7 However, lym-
hoscintigraphic studies have shown that autologous lymph 
odes incorporate only at a low frequency into the existing 
ymphatic vasculature, 4 , 8 so most of the operated patients 
ust continue using compression garments. 
Vascular endothelial growth factor C (VEGF-C) is the 
ost selective growth factor that stimulates the forma- 
ion of new lymphatic vessels in a process called lym-
hangiogenesis. Adenoviral VEGF-C gene transfer results 
n transient VEGF-C overexpression in the targeted tis- 
ue. 9 , 10 During the first two weeks after the transfer, it
timulates robust growth of lymphatic capillaries in ex- 
erimental models. Thereafter, the adenoviral vector is 
liminated by the host immune system, and VEGF-C down- 
egulation leads to the regression of some of the gen- 
rated lymphatic vessels. 10 However, the newly formed 
essels with lymphatic flow stabilize and mature into col- 
ecting lymphatic vessels spontaneously over the course of 
ix months. 9-12 
Several studies have shown that the transplantation of 
EGF-C transfected lymph nodes results in the restora- 
ion of a functional lymphatic network in the damaged 
rea. 9 , 11 , 13 , 14 In these experimental studies, a combined 
rowth factor treatment with lymph node transfer was used 
o incorporate lymph nodes into the pre-existing lymphatic 
essel network in the affected axillary/inguinal area. The ationale for using VEGF-C with lymph node transfer is that
EGF-C increases successful lymphatic vessel anastomosis 
hat incorporates the transferred nodes. In a porcine model,
dministration of Lymfactin R © in the fat tissue surrounding 
he single inguinal lymph node promoted the growth of af-
erent and efferent lymphatic vessels, resulting in improved 
ymphatic flow, as seen in postoperative lymphangiogra- 
hy. 11 , 12 In this large animal model, regrown lymph vessels 
panned a much wider gap and often became attached to
he lymph node, both afferently and efferently. 12 , 13 
In secondary lymphedema associated with the treatment 
f breast cancer, the affected lymphatic network is usually 
estricted to the axillary area. 15 Results from the above-
entioned experimental models suggest that in this set- 
ing, expression of the VEGF-C vector for 1–2 weeks is suffi-
ient to rebuild damaged lymphatic vessels. Once the newly
ormed lymphatic vasculature becomes functional, the lym- 
hatic vessels stabilize and further mature into collective 
ymphatic vessels in the target tissue. 
Human lymph nodes express VEGF-C, which is also 
ound in the axillary wound exudate after microvascu- 
ar lymph node transfer. 4 , 5 Results from preclinical lym- 
hedema models employing VEGF-C or VEGF-D have demon- 
trated the ability of these factors to induce growth of
ew lymphatic vessels, 16 , 17 thus providing a biological ba- 
is for VLNT surgery. Not all patients benefit from VLNT,
hich may partly be explained by the temporal and spa-
ial differences in lymph node VEGF-C expression. 5 , 18 Re- 
ent studies have shown that in addition to VEGF-C, lym-
hangiogenesis is regulated by a coordinated expression of 
ro- and anti-inflammatory cytokines. 19-21 Further, fibro- 
is, scarring and a Th2-dominant CD4 T cell immune re-
ponse are known to be key inhibitors of lymphatic regen-
ration. 21 , 22 Thus, combining VLNT surgery and Lymfactin R ©
rovides a promising approach for a curative treatment 
f secondary lymphedema. Lymphedema is a debilitating 
ondition, and no curative treatment is available at the
oment. VLNT surgery has become a popular treatment 
f lymphedema, although the results of surgery are vari-
ble. 6 In this article, we present the short-term safety and
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vessels were not anastomosed. tolerability results of the Lymfactin R © Phase I trial, where
microsurgical lymph node transfer (VLNT) surgery and ade-
noviral VEGF-C treatment were combined. 
Methods 
The study protocol was approved by the Finnish Medical
Agency (FIMEA) and the Ethics Committee (EC) of Helsinki
Hospital District. The study identifier number at ClinicalTri-
als.gov is NCT02994771. 
Patient selection 
Female patients aged 18–70 years with secondary lym-
phedema associated with the treatment of breast cancer
were eligible for inclusion in the study. Their body mass
index had to be between 18 and 32. The criteria required
that the initial staging of their cancer was N0 or N1 with
only intracapsular lymph node metastasis present in ≤ three
lymph nodes. At least 2 years of breast cancer treatment
and/or the end of chemotherapy and/or radiotherapy (ex-
cluding endocrine and/or aromatase inhibitor treatment)
without evidence of recurrent or active breast cancer were
required. 
The criteria regarding lymphedema required the patients
a) to have undergone sentinel lymph node biopsies and/or
lymph node resection in the axilla on the affected side of
their breast cancer with b) regular garment use as a com-
pression treatment for lymphedema in the affected arm,
and to have c) the volume of the affected arm be over
10% larger than the unaffected arm following 7 days with-
out compression garments, d) the presence of pitting edema
in the affected arm without compression garments, and e)
lymphedema symptoms for ≤ 5 years. 
Exclusion criteria included an initial N2/N3 or T4 staging
of breast cancer or an inflammatory breast cancer at the
time of the original diagnosis, evidence or history of a neo-
plasm other than breast cancer (except basal cell carcinoma
or cervical in situ carcinoma), pregnancy, lactation and pre-
vious treatment or participation in a trial of a gene therapy
product. 
Study design 
This was a first-in-human Phase I multi-center, open-label,
uncontrolled dose escalation study to evaluate the safety,
tolerability and biodistribution of the vector of a single
dose of Lymfactin R © in female patients with secondary lym-
phedema associated with breast cancer treatment. Treat-
ment with Lymfactin R © was combined with VLNT surgery.
The study-related procedures to assess the effects of
Lymfactin R © were standardized across all participating sites.
Two dose cohorts were included: Cohort 1 with the dose
of 1 × 10 10 vp (or 6 × 10 8 plaque forming units [pfu]) aimed
at testing the safety/tolerability and Cohort 2 with the dose
of 1 × 10 11 vp (or 6 × 10 9 pfu) aimed to be the therapeutic
dose. The protocol included detailed dose escalation strate-
gies in the presence or absence of dose limiting toxicities
(DLT). In the absence of DLT’s, the first patient in Cohort 1was monitored for DLT’s for 30 days post dosing. Thereafter,
two additional patients were dosed and monitored for 30
days. After this, the dose escalation continued in Cohort 2
with similar within cohort monitoring as described for the
Cohort 1. Once this was completed, additional 9 patients
were included in the Cohort 2. In total, 3 and 12 patients
were treated in Cohort 1 and 2. 
Study visits and data collection 
At screening, a written informed consent was obtained. De-
mographic data, medical history, history of breast cancer,
and history of lymphedema were recorded at the screening
visit (Visit 1A). A complete physical examination was carried
out at the screening visit (Visit 1A), at Days 0 (Visit 2) and
7, and at Months 1, 3, 6 and 12 (Visits 4–8A). A PET-CT scan
of the chest and abdomen 45–15 days before treatment was
performed as the final screening procedure. 
Blood and urine samples for the determination of clinical
chemistry, hematology and urinalysis parameters were col-
lected at screening and at Days 0, 7, 30, 90 and 180 and as
clinically indicated. 
Adverse events (AEs) and serious adverse events (SAEs)
were carefully collected and graded using the Common Ter-
minology Criteria for Adverse Event Version 4.03 (CTCAE
4.03). 
Limb volume was quantified using the method described
by Brorson 23 . Limb diameter was calculated every 4 cm
starting from the wrist and the volume difference of arms
calculated using a truncated cone formula. Quantitative
lymphoscintigraphy (40MBq of technetium-labeled sulfur
nanocolloid 99mTc-Nanocoll, GE healthcare) with calcula-
tion of the transport index was used for lymphatic function
measurement 24 . 
Operative technique and administration of 
Lymfactin R ©
The VLNT flap based on the superficial circumflex iliac ves-
sels was raised as previously described. 4 , 5 , 25 For some pa-
tients, this was combined with breast reconstruction us-
ing a lower abdominal flap (DIEP or ms-TRAM flap). A two-
team surgical approach was used. Simultaneously, the axil-
lary scar was removed and the recipient thoracodorsal ves-
sels or its branches were prepared. 
Lymfactin R © concentrate was stored below -60 °C before
thawing and dilution with sterile saline for the administra-
tion. Once diluted, the solution was stored at 2 – 8 °C un-
til administration within 4 hours of the dilution. After the
lymph node flap was raised, the flap was positioned on a
sterile table and Lymfactin R © was administered ex vivo as a
perinodal injection into the fat tissue of the flap contain-
ing the lymph nodes. The solution was injected into the
proximal and the distal parts of the flap at 2 - 4 injection
sites each avoiding the flap pedicle. Superficial circumflex
iliac vessels were anastomosed to thoracodorsal vessels or
their branches, and in the case of simultaneous breast re-
construction, inferior epigastric vessels were anastomosed
to internal mammary or thoracodorsal vessels. Lymphatic
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Figure 1 Flow diagram of patient screening, treatment 
and retention of 16 study participants with breast cancer 
treatment–associated secondary lymphedema. One patient was 
not included because of abnormal findings in PET-CT imaging. 
Patients were enrolled in two different dose groups: Cohort 
1 received a dose of 1 × 10 10 and Cohort 2 a dose of 1 × 10 11 
viral particles. There were no further withdrawals from the 
study. 
Table 1 Patient characteristics. 
Cohort 1 Cohort 2 
Age (y) 52.7 ±15 55.5 ±6.7 
Weight (kg) 68.3 ±8.6 76.3 ±12.7 
Height (m) 1.7 ±0.1 1.6 ±0.1 
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moses. To minimize possible donor site morbidity, 25 , 26 reverse 
entinel node mapping was performed using Technetium 
sotope injection (40MBq of technetium-labeled sulfur 
anocolloid (99mTc-Nanocoll, GE healthcare) in a volume of 
.1–0.2 ml) and gamma imaging. The injection was placed 
ntradermally between the first and second digit in the 
onor foot. During the operation, the sentinel nodes were 
etected with a gamma detector, and dissection near these 
odes was avoided. 
Clinical flap monitoring and, in addition, tissue oxygen 
ensor (Licox R ©, GMS, Kiel-Mielkendorf, Germany) in some 
atients were used to monitor the perfusion of the flap 
or three to four days postoperatively. Manual lymphatic 
rainage was started two weeks postoperatively, and it con- 
inued twice a week for three months after the surgery. 
or the first 12 months postoperatively, all patients used 
n elastic compression dressing on the treated arm 24 hours 
er day. 
tudy objectives 
he primary aim of the study was to evaluate the safety
nd tolerability of a single dose of Lymfactin R © administered 
s a perinodal injection in association with VLNT surgery in 
atients with secondary lymphedema associated with the 
reatment of breast cancer. For the long-term safety re- 
ults, the patients are monitored annually up to 5 years 
ost-treatment using CT scans of the chest and abdomen 
nd contact via telephone. The secondary objectives were 
o establish the appropriate safe and well-tolerated dose of 
ymfactin R © for use in future studies in patients with sec- 
ndary lymphedema and to determine the biodistribution 
f the Lymfactin R © vector in blood and the development of
ymfactin R ©-specific antibodies following a single dose. Ef- 
cacy will be monitored up to 36 months post-treatment 
sing volumetry measurements, lymphoscintigraphy and 
ymphedema Quality of Life Inventory questionnaires 
LQOLI). 
iodistribution (PCR) and analysis of 
ymfactin R ©-specific antibodies 
he presence of the Lymfactin R © genome was analyzed from 
lood samples taken at baseline and at 7, 30 and 90 days
fter treatment (please see supplementary methods for 
rotocol). The concentration of anti-Lymfactin R © antibodies 
IgG) was analyzed from serum samples taken at baseline 
nd at 30, 90 and 180 days after treatment (please see sup-
lementary methods for protocol). 
esults 
articipants 
etween December 2016 and February 2018, 15 female 
ostmastectomy lymphedema patients were included in the 
tudy. One patient did not pass screening due to unex-
ected findings in PET-CT and was therefore not included n the study ( Figure 1 ). There have been no further with-
rawals. Patient characteristics are summarized in Table 
 . The mean age of the patients was 54.9 ±8.3. The mean
eight was 165 ±6.2 cm and weight 74.7 ±12.2 kg. The mean
ody mass index was 27.1 ±3.7. Breast cancer and lym-
hedema history are presented in Table 2 . Breast cancer
NM staging of the patients was T1N0M0 (2/15), T1N1M0
3/15), T2N0M0 (1/15) or T2N1M0 (9/15). Surgery (lumpec- 
omy/mastectomy and sentinel node biopsy/axillary dis- 
ection) was the primary treatment method (15/15). Of 
he patients, 11 of the 15 had received radiation therapy
nd 14 had undergone chemotherapy as additional adjuvant 
reatments for breast cancer. The average volume differ- 
nce preoperatively was 590 ±504 ml with compression and
he average transport index of the affected arm in lym-
hoscintigraphy was 32.1 ±12.7. 
peration 
 total of 15 patients with stage I or II upper extremity lym-
hedema underwent VLNT. Of these, 10 patients underwent 
imultaneous breast reconstruction and VLNT and 5 VLNT 
nly. One patient needed a re-operation due to hematoma
f the flap donor site. There were no flap losses and no
e-operations were needed regarding microvascular anasto- 
1616 P. Hartiala, S. Suominen and E. Suominen et al. 
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 Safety profile 
According to the dose escalation protocol, 3 patients were
included in Cohort 1 and they received the lower dose of
1 × 10 10 vp. No DLTs were observed during the follow-up
time, so the next patients were included in Cohort 2 and re-
ceived a dose of 1 × 10 11 vp, which was the pre-determined
maximum dose. No DLTs were observed in Cohort 2, and the
study was completed with the pre-determined maximum
dose. A total of 15 patients received study treatment. 
AEs are listed in Table 3. Of all patients, 11 (73.3%) had
adverse events during the screening period before treat-
ment (data not shown), 10 (66.7%) during the hospital stay
( Table 3A ) and 15 (100%) during the follow-up visits ( Table
3B ). The most common adverse events were common cold,
fever, gastroenteritis, pain in the operation area, headache,
muscle ache and elevated liver enzymes. All adverse events
to date (minimum follow-up 12 months) are listed in Table
3.The follow-up is longer for Cohort 1 patients as they were
treated first, resulting in a larger number of AEs. The safety
profiles for Cohort 1 and 2 were similar. There were a to-
tal of three SAEs: two erysipelas infections requiring hos-
pitalization and one postoperative hematoma in the groin.
No deaths or breast cancer recurrences occurred during the
12-month follow-up. One patient presented with basal cell
carcinoma during the follow-up. 
Clinically significant elevations of liver enzyme values (P-
ALAT, P-ASAT, P-AFOS, P-Bil) were detected in four patients
(one patient in Cohort 1 and three in Cohort 2) pre- and
post-treatment ( Figure 2 A-D). In all cases, the liver enzymes
normalized within a few weeks. Single abnormal liver en-
zyme values were also detected in six other patients. How-
ever, none of these were considered clinically relevant by
their treating physician. No other clinically relevant abnor-
malities were found in the laboratory results. The lympho-
cyte, monocyte and neutrophil counts were normal follow-
ing treatment ( Figure 2 E-G). One patient had elevated lym-
phocyte and monocyte values at the time of screening, and
one patient had an elevated neutrophil count at 90 days.
However, these were normalized in the follow-up. 
Biodistribution of the vector and 
Lymfactin R ©-specific antibodies 
Lymfactin R © treatment did not result in detection of the viral
genome in any of the patients’ blood (data not shown), nor
was there an increase in the concentration of Lymfactin R ©-
specific antibodies post-treatment ( Figure 3 ). It should be
noted that there was high variability in antibody concentra-
tions before treatment, most likely because Lymfactin R © has
an identical viral capsid with human adenovirus serotype 5
(Ad5). Thus, previous exposure to Ad5 and especially any re-
cent adenoviral infection would have a major effect on the
concentration. In one patient, the concentration was very
high before treatment, likely due to a recent Ad5 infection.
In another patient, the concentration increased between 90
and 180 days post-treatment, also likely because of an ade-
noviral infection rather than an effect of the Lymfactin R ©
treatment. In conclusion, it seems that there was no sig-
nificant immune activation because of Lymfactin R © after its
local administration. 
1617 
Table 3A Adverse events during treatment and hospital stay. 
Primary System Organ Class Lowest Level Term C1 (N = 3) C2 (N = 12) Total (N = 15) 
Total Total 4 3 (100.0) 9 7 (58.3) 13 10 (66.7) 
Gastrointestinal disorders Total 1 1 (8.3) 1 1 (6.7) 
Oral aphthae 1 1 (8.3) 1 1 (6.7) 
General disorders and administration site conditions Total 1 1 (8.3) 1 1 (6.7) 
Medical device site burn 1 1 (8.3) 1 1 (6.7) 
Infections and infestations Total 1 1 (8.3) 1 1 (6.7) 
Common cold 1 1 (8.3) 1 1 (6.7) 
Injury, poisoning and procedural complications Total 2 2 (66.7) 2 2 (13.3) 
Post-operative hematoma 1 1 (33.3) 1 1 (6.7) 
Post-operative pain 1 1 (33.3) 1 1 (6.7) 
Investigations Total 1 1 (33.3) 5 4 (33.3) 6 5 (33.3) 
Elevated liver enzymes 1 1 (33.3) 3 3 (25.0) 4 4 (26.7) 
Hemoglobin low 2 2 (16.7) 2 2 (13.3) 
Reproductive system and breast disorders Total 1 1 (8.3) 1 1 (6.7) 
Abnormal menstruation 1 1 (8.3) 1 1 (6.7) 
Vascular disorders Total 1 1 (33.3) 1 1 (6.7) 
Hypertension 1 1 (33.3) 1 1 (6.7) 
Figure 2 Kinetics of P-ALAT (A), P-ASAT (B), P-AFOS (C), P-Bil (D) values during screening, treatment and follow-up. There was an 
increase in liver enzyme concentrations at Day 7 after treatment in 4 patients. Patient 301 with a grade 2 increase is marked with 
the dashed line. Kinetics of peripheral blood lymphocyte (E), monocyte (F) and neutrophil (G) counts during screening, treatment 
and follow-up. One patient had elevated monocyte and lymphocyte count prior to treatment (dashed line) and one patient at 90 
days after treatment. These were normalized during the follow-up. 
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Table 3B Adverse events during follow-up. 
Primary System Organ Class Lowest Level Term C1 (N = 3) C2 (N = 12) Total (N = 15) 
Total Total 23 3 (100.0) 55 12 (100.0) 78 15 (100.0) 
Cardiac disorders Total 1 1 (8.3) 1 1 (6.7) 
Sinus arrythmia 1 1 (8.3) 1 1 (6.7) 
Gastrointestinal disorders Total 1 1 (33.3) 7 4 (33.3) 8 5 (33.3) 
Abdominal pain 1 1 (8.3) 1 1 (6.7) 
Constipation 2 1 (8.3) 2 1 (6.7) 
Diarrhea 1 1 (8.3) 1 1 (6.7) 
Tooth decay 1 1 (8.3) 1 1 (6.7) 
Tooth pain 1 1 (8.3) 1 1 (6.7) 
Upper abdominal pain 1 1 (33.3) 1 1 (6.7) 
Vomiting 1 1 (8.3) 1 1 (6.7) 
General disorders and administration site 
conditions 
Total 4 1 (33.3) 2 2 (16.7) 6 3 (20.0) 
Fever 4 1 (33.3) 2 2 (16.7) 6 3 (20.0) 
Immune system disorders Total 1 1 (8.3) 1 1 (6.7) 
Allergy to arthropod bite 1 1 (8.3) 1 1 (6.7) 
Infections and infestations Total 4 2 (66.7) 13 10 (83.3) 17 12 (80.0) 
Common cold 1 1 (8.3) 1 1 (6.7) 
Erysipelas 3 3 (25.0) 3 3 (20.0) 
Flu 3 1 (33.3) 5 5 (41.7) 8 6 (40.0) 
Infected skin atheroma 1 1 (33.3) 1 1 (6.7) 
Otitis 1 1 (8.3) 1 1 (6.7) 
Post-operative infection 1 1 (8.3) 1 1 (6.7) 
Sinusitis 2 2 (16.7) 2 2 (13.3) 
Injury, poisoning and procedural complications Total 2 1 (33.3) 5 3 (25.0) 7 4 (26.7) 
Drain site complication 2 1 (8.3) 2 1 (6.7) 
Post-operative fistula 1 1 (8.3) 1 1 (6.7) 
Post-operative swelling 1 1 (33.3) 1 1 (6.7) 
Wound complication 1 1 (8.3) 1 1 (6.7) 
Wound decomposition 1 1 (8.3) 1 1 (6.7) 
Wound dehiscence 1 1 (33.3) 1 1 (6.7) 
Investigations Total 1 1 (8.3) 1 1 (6.7) 
Elevated liver enzymes 1 1 (8.3) 1 1 (6.7) 
Metabolism and nutrition disorders Total 1 1 (33.3) 1 1 (6.7) 
Hypercalcemia 1 1 (33.3) 1 1 (6.7) 
Musculoskeletal and connective tissue disorders Total 4 2 (66.7) 3 3 (25.0) 7 5 (33.3) 
Bursitis 1 1 (8.3) 1 1 (6.7) 
Muscle spasm 1 1 (33.3) 1 1 (6.7) 
Joint pain 1 1 (8.3) 1 1 (6.7) 
Muscle ache 2 1 (33.3) 2 1 (6.7) 
Pain in (r) foot 1 1 (8.3) 1 1 (6.7) 
Shoulder pain 1 1 (33.3) 1 1 (6.7) 
Neoplasms benign, malignant and unspecified Total 1 1 (33.3) 1 1 (8.3) 2 2 (13.3) 
Basal cell carcinoma 1 1 (33.3) 1 1 (6.7) 
Keratoacanthoma 1 1 (8.3) 1 1 (6.7) 
Nervous system disorders Total 2 1 (33.3) 12 4 (33.3) 14 5 (33.3) 
Headache 2 1 (33.3) 11 3 (25.0) 13 4 (26.7) 
Sensory loss 1 1 (8.3) 1 1 (6.7) 
Psychiatric disorders Total 1 1 (8.3) 1 1 (6.7) 
Depression 1 1 (8.3) 1 1 (6.7) 
Respiratory, thoracic and mediastinal disorders Total 2 1 (8.3) 2 1 (6.7) 
Cough 1 1 (8.3) 1 1 (6.7) 
Sniffles 1 1 (8.3) 1 1 (6.7) 
Skin and subcutaneous tissue disorders Total 4 2 (66.7) 6 5 (41.7) 10 7 (46.7) 
Blisters 1 1 (8.3) 1 1 (6.7) 
( continued on next page ) 
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Table 3B ( continued ) 
Primary System Organ Class Lowest Level Term C1 (N = 3) C2 (N = 12) Total (N = 15) 
Dry skin 1 1 (8.3) 1 1 (6.7) 
Dry skin face 1 1 (8.3) 1 1 (6.7) 
Erythema of extremities 2 1 (33.3) 2 1 (6.7) 
Hair loss 1 1 (33.3) 1 1 (6.7) 
Hidradenitis 1 1 (8.3) 1 1 (6.7) 
Pruritus 1 1 (8.3) 1 1 (6.7) 
Scar pain 1 1 (8.3) 1 1 (6.7) 
Sugillation 1 1 (33.3) 1 1 (6.7) 
Presented as number of events, number of patients, (percentage of all patients). 
Figure 3 Lymfactin R ©-specific IgG concentrations of the patients during screening, treatment and follow-up. 
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Figure 4 Operation and treatment protocol. A) Lymphatic tis- 
sue from the lower abdominal wall is harvested as a vascular- 
ized free flap. B) Lymfactin R © is injected into the distal edges 
of the lymphatic flap to enhance lymphangiogenesis and subse- 
quent lymphatic network maturation. C) The lymphatic flap is 
inserted into the axilla to replace the excised scar tissue. iscussion 
e present the short-term safety results of a Phase I 
ulti-center study of the prolymphangiogenic growth factor 
ector Lymfactin R © in female patients with breast cancer–
ssociated lymphedema. Lymfactin R © was combined with 
LNT surgery after complete scar removal from the axilla. 
here were no dose-limiting toxicities, thus all the patients 
n Cohort 2 received the pre-determined maximum dose. 
The combination of VLNT and Lymfactin R © treatment has 
any theoretical advantages ( Figure 4 ). First, the surgical 
peration includes the removal of all axillary scar tissue. 
he lymph node flap provides healthy adipose tissue, lymph 
odes and lymphatic vessels to the axillary region, thus fill-
ng the vessel gap and replacing the fibrotic scar in the ax-
lla with healthy, well-vascularized tissue. The perinodal in- 
ection of VEGF-C growth factor induces rapid lymphangio- 
enesis, followed by a maturation of the lymphatic network 
ver several months. 9 A longer follow-up will reveal the fi-
al safety and efficacy of this novel treatment. 
The general condition of the treated patients was good 
uring follow-up, with normal vital signs and physical ex- 
mination. The reported AEs in hematotology and clini- 
al chemistry may be due to concomitant treatment, long- 
asting and extensive surgical operations, and the use of 
oth anesthetics and strong analgesics, which have been 
eported to induce transient elevation of liver transami- 
ases. 27 , 28 Adenoviruses are cleared from the bloodstream 
ainly by Kupffer cells in the liver, 29 which may cause in-
ammatory responses and also lead to the temporary ele- 
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 vation of liver enzymes. Based on previous studies, the re-
lationship between adenoviral therapy and the elevation of
the liver enzymes is not well established. In a study using
a single dose of replication-deficient adenoviral gene ther-
apy locally (dose 2 × 10 10 plaque-forming units), no eleva-
tion of liver enzymes could be detected. 30 This is consis-
tent with a study using oncolytic adenovirus therapy. Three
doses (1 × 10 12 viral particles per dose) were administered
i.v. within five days, and no adverse events related to liver
enzyme elevation were reported. 31 However, in a study us-
ing repeated local injections of replication-competent on-
colytic adenoviral gene therapy in solid tumor treatment,
elevated liver enzymes were noted in roughly 20% of the
patients. In this study, the overall dose was 2.7 × 10 11 -
2.7 × 10 12 viral particles, and viral genome was detected
in the bloodstream. In the present study, Lymfactin R © DNA
was not detected in the bloodstream of the patients, and
the treatment did not increase the serum IgG antibody titer
against the vector. Based on these results, the systemic
presence of Lymfactin R © seems limited. Thus, it is unlikely
that the elevation of the liver enzymes would be a result of
the adenoviral vector. 
In this article, we present the safety results after 12-
months follow-up. At this stage it can be deduced that
Lymfactin R © in combination with VLNT surgery is safe im-
mediately after the operation and during short-term follow-
up and no SAEs were regarded drug- or vector-related.
We chose to publish the early safety results because we
feel that plastic surgeons treating lymphedema need to be
aware of this novel trial and promising safety result short-
term on. However, the ultimate safety results and espe-
cially the oncological safety of Lymfactin R © will require a
long 5-year follow-up and a larger patient population. In the
Phase I trial, one can not separate the effects of the VLNT
surgery and Lymfactin R © treatment as all patients have re-
ceived Lymfactin R © treatment. The Phase II trial, a random-
ized placebo controlled trial, aims to answer the question
about efficacy of this novel treatment as half of the patients
are randomized to receive only placebo in combination with
VLNT surgery. 
As the next phases of the study will require larger pa-
tient populations, breast cancer recurrence will inevitably
occur in at least some of these patients. Loco-regional
breast cancer recurrence rates vary depending on tumor
subtype. A recent article reported an overall rate of 1.6–
5% during a mean follow-up of 69.5 months. 32 The highest
rates have been reported for triple-negative subtypes of
breast cancer (7.4%). 33 Although VEGF-C expression is as-
sociated with a poor prognosis and increased metastasis risk
in some cancer types, for breast cancer, the data is contro-
versial. 34-37 In this study, Lymfactin R © was injected into the
healthy lymphatic tissue flap ex vivo to minimize the theo-
retical effects on the dormant tumor cells in the patient’s
axilla. 
At the moment, no curative treatment is available for
lymphedema patients. Thus, Lymfactin R © treatment com-
bined with lymph node transfer surgery could offer new
hope for lymphedema patients. A randomized placebo con-
trolled Phase II study, in which the patients will be evaluated
for the efficacy and safety of Lymfactin R © for several years,
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